Top > Search of International Patents > BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION

BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION

Foreign code F170009239
File No. (S2016-0508-N0)
Posted date Sep 21, 2017
Country WIPO
International application number 2017JP008579
International publication number WO 2017150720
Date of international filing Mar 3, 2017
Date of international publication Sep 8, 2017
Priority data
  • P2016-041740 (Mar 4, 2016) JP
Title BIOMARKER FOR FIBROSIS EVALUATION, EVALUATION METHOD FOR FIBROSIS, AND BACTERIAL CULTURE MEDIUM FOR EVALUATION
Abstract [Problem] To provide an evaluation method for fibrosis and a biomarker for fibrosis evaluation.
[Solution] A biomarker for fibrosis evaluation, the biomarker being for detection in biological samples obtained from test animals and including at least one type of bacteria selected from the group the consists of Christensenella , Clostridium , Halomonas , and Shewanella . The fibrosis may include, for example, pulmonary fibrosis (including IPF), renal fibrosis, or the like.
Outline of related art and contending technology BACKGROUND ART
In certain tissue fibrosis, fibrosis often lose the original function of the known. Among these as occurring in the lung, idiopathic pulmonary fibrosis (Idiopathic pulmonary fibrosis: hereinafter, referred to as' IPF ') is. IPF is, progressive lethal disease. The median survival after a definitive diagnosis of IPF is -4 years and 2 years, the prognosis of the cancer is worse than normal. For the pathology consists IPF has not been determined, the treatment improved survival is not known. And the gun between IPF, clinical course and disease pathogenesis, in point similar to the behavior of the molecule. Is IPF patients and cancer patients, strongly resistant to treatment, survival period is short. In addition, environmental factors (for example, tobacco) lethal exposed to a, or delay of apoptosis with common molecular abnormalities μA. However, the treatment of cancer patients IPF similarities with the patient submitted hypothesis is not described. On the other hand, the environmental factors such bacteria, and the host response or pathological factors and is not one of the indications. The amount of bacteria in lung lavage fluid for correlation with the progression of pulmonary fibrosis is studies. According to that study, the amount of bacteria (particularly S. Streptococcus, genus Staphylococcus) often in patients with fast progression of the pathological condition, acute exacerbations frequently occurred and the like have been reported (non-patent document 1). In addition, the amount of the bacteria in the bronchial pulmonary fibrosis in lung lavage fluid and a comparison was made between healthy subjects (non-patent document 2) is present in the article. According to this paper, the bronchial pulmonary fibrosis in lung lavage fluid obtained from a patient is, only the species is also detected in healthy subjects have been observed. At this time, bacteria in the lung tissue has not been studied. Kristen senella organism according to the present invention is, in the intestine has been detected from the (non-patent document 3) report. Halomonas organism is, in a person's blood and report detected from the (non-patent document 4, 5) as the inspection method of the flora, reach up to the method and the oligo type (non-patent document 6), to a method of visualizing bacteria (non-patent document 7) have been known.
Scope of claims (In Japanese)[請求項1]
被験動物から得られた生体サンプルに検出される線維症評価用バイオマーカであって、クリステンセネラ(Christensenella)、クロストリジウム(Clostridium)、ハロモナス(Halomonas)及びシュワネラ(Shewanella)からなる群から選択される少なくとも一種の細菌を含む線維症評価用バイオマーカ。
[請求項2]
前記生体サンプルが、唾液、血液、組織表面の洗浄液及び切り取られた組織からなる群から選択される少なくとも一つである請求項1に記載の線維症評価用バイオマーカ。
[請求項3]
前記線維症が、肺線維症及び腎線維症、からなる群から選択される少なくとも一つである請求項1または2に記載の線維症評価用バイオマーカ。
[請求項4]
被験動物から得られた生体サンプルについて、クリステンセネラ(Christensenella)、クロストリジウム(Clostridium)、ハロモナス(Halomonas)及びシュワネラ(Shewanella)からなる群から選択される少なくとも一種の細菌を検出する線維症の評価方法。
[請求項5]
前記検出が、細菌に由来する核酸を検出するものである請求項4に記載の線維症の評価方法。
[請求項6]
(1)ハロモナス(Halomonas)を含み、(2)クリステンセネラ(Christensenella)、クロストリジウム(Clostridium)及びシュワネラ(Shewanella)からなる群から選択される少なくとも一種の細菌を含む細菌群のための線維症評価用細菌培地。
[請求項7]
請求項6に記載の細菌用培地であって、炭素源と窒素源とミネラルと0.34M~5Mの塩化ナトリウムとを含む線維症評価用細菌培地。
[請求項8]
(1)ハロモナス(Halomonas)を含み、(2)クリステンセネラ(Christensenella)、クロストリジウム(Clostridium)及びシュワネラ(Shewanella)からなる群から選択される少なくとも一種の細菌を含む細菌群を凍結した線維症評価用凍結細菌。
[請求項9]
(1)ハロモナス(Halomonas)を含み、(2)クリステンセネラ(Christensenella)、クロストリジウム(Clostridium)及びシュワネラ(Shewanella)からなる群から選択される少なくとも一種の細菌を含む細菌群を乾燥した線維症評価用乾燥細菌。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • MIE UNIVERSITY
  • Inventor
  • GABAZZA, Esteban
  • GABAZZA, Corina
  • CANN, Isaac
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Please contact us by E-mail or facsimile if you have any interests on this patent.

PAGE TOP

close
close
close
close
close
close